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Abstract
Chronic inflammation may play a role in prostate cancer carcinogenesis. In that 
context, our objective was to investigate the role of nonsteroidal anti- inflammatory 
drugs (NSAIDs) in prostate cancer risk based on the EPICAP data. EPICAP is 
a population- based case–control study carried out in 2012–2013 (département 
of Hérault, France) that enrolled 819 men aged less than 75 years old newly 
diagnosed for prostate cancer and 879 controls frequency matched to the cases 
on age. Face to face interviews gathered information on several potential risk 
factors including NSAIDs use. Odds ratios (ORs) and their 95% confidence 
intervals (CIs) were calculated using unconditional logistic regression models. 
All- NSAIDs use was inversely associated with prostate cancer: OR 0.77, 95% 
CI 0.61–0.98, especially in men using NSAIDs that preferentially inhibit COX- 2 
activity (OR 0.48, 95% CI 0.28–0.79). Nonaspirin NSAIDs users had a decreased 
risk of prostate cancer (OR 0.72, 95% CI 0.53–0.99), particularly among men 
with an aggressive prostate cancer (OR 0.49, 95% CI 0.27–0.89) and in men 
with a personal history of prostatitis (OR 0.21, 95% CI 0.07–0.59). Our results 
are in favor of a decreased risk of prostate cancer in men using NSAIDs, par-
ticularly for men using preferential anti- COX- 2 activity. The protective effect 
of NSAIDs seems to be more pronounced in aggressive prostate cancer and in 
men with a personal history of prostatitis, but this needs further investigations 
to be confirmed.
Introduction
Prostate cancer is the most common male cancer in west-
ernized countries with an estimated 1.1 million men diag-
nosed with prostate cancer in 2012 worldwide [1]. In France, 
more than 50,000 cases of prostate cancer were diagnosed 
in 2011, with almost 9000 related deaths that same year 
making it the third cause of cancer- related mortality [2].
Except age, ethnic origin, and family history of prostate 
cancer that are well- established nonmodifiable risk factors, 
the etiology of prostate cancer remains largely unknown. 
Accumulating epidemiological, biological, genetic, and 
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experimental evidence suggested that chronic inflammation 
may be associated either with initiation or progression 
of several cancers, including prostate cancer [3–6]. Indeed, 
inflammatory cells as well as the chemokines and cytokines 
they produce confer a microenvironment favorable to 
tumor growth, by increasing the production of reactive 
oxygen species leading to oxidative DNA damage and 
reduce DNA repair, and tumor progression by promoting 
angiogenesis [3–5].
Regarding prostate cancer, the presence of inflammatory 
infiltrations localized near zones of proliferative inflam-
matory atrophy and prostatic intraepithelial neoplasia, 
considered to be potentially precancerous prostatic lesions, 
has contributed to reinforce the hypothesis of a possible 
link between chronic inflammation and prostate cancer 
[7]. Moreover, prostate tissues with histological evidence 
of inflammation were more likely to develop prostate cancer 
than those without inflammation [8]. The mechanism of 
inflammation is based on the action of the cyclooxygenase 
(COX), enzyme that catalyzes messenger molecules in 
inflammation pathways [9]. There are two distinct isoforms 
of the COX enzyme: COX- 1, constitutively expressed in 
most tissues and involved in physiological functions, and 
COX- 2, expressed in several tissues during inflammation. 
Indeed, an overexpression of COX- 2 in human prostate 
cancer tissue compared to benign prostate tissue has been 
reported [10]. Therefore, nonsteroidal anti- inflammatory 
drugs (NSAIDs), used for their analgesic and antipyretic 
properties, and at higher doses, for their anti- inflammatory 
effects, have received attention for their potential as chemo-
preventive drugs against cancer. They may be characterized 
according to their ability to preferentially inhibit COX- 1 
as aspirin or COX- 2 as coxibs or oxicams [11].
Most epidemiological studies reported an inverse asso-
ciation between aspirin and cancer risk, especially for 
colorectal cancer [12]. Modest inverse associations were 
also reported with aspirin use and prostate cancer occur-
rence in observational studies or meta- analysis [13–17]. 
Evidence for nonaspirin NSAIDs (NA- NSAID) use and 
inverse association with cancer are even more scarce, with 
at least three observational studies showing even a posi-
tive association with prostate cancer risk [18–20] and 
others showing null or weak negative association [21–28]. 
Meta- analysis could not give strong conclusions because 
of striking heterogeneity between studies [14–16, 29], with 
only one showing modest inverse association [16] and 
three of them null association.
Few of these studies provided data on type of NSAIDs 
and anti- COX preferential activity, frequency, duration, 
recency of use, circumstances of prescription, and addressed 
the aggressiveness of cancer.
In this context, our main objective was to study the 
association between NSAIDs use (aspirin and nonaspirin 




EPICAP (EPIdemiology of Prostate CAncer) is a 
population- based case–control study which details of the 
study protocol have been published elsewhere [30]. Cases 
were men newly diagnosed with histologically confirmed 
prostate cancer between 2012 and 2013, aged less than 
75 years old, and living in the département of Hérault, 
France at the time of diagnosis. The identification of the 
cases was realized by clinical research nurses, specifically 
trained for the study, by active search in all public and 
private cancer care centers of the département. Only cases 
who gave their informed consent were included in the 
study. Controls were men randomly selected in the general 
population, frequency matched to the cases, living in the 
département of Hérault as the cases, and with no history 
of prostate cancer at the time of inclusion. Quotas by 
age were established as a preliminary to yield the control 
group similar to the case group in terms of age in order 
to achieve frequency matching (5 year age group). Quotas 
by socioeconomic status (SES) were also set a priori to 
control for potential selection bias arising from differential 
participation rates across SES categories. These quotas by 
SES were calculated from the census data available in the 
département of Hérault, in order to obtain a distribution 
by SES among controls identical to the SES distribution 
among general male population, conditionally to age.
A total of 1098 cases and 1109 controls were eligible, 
of which 819 and 879, respectively, were included in the 
study representing a participation rate of 75% for cases 
and 79% for controls.
Data collection
Trained clinical research nurses conducted face to face 
interviews of cases and controls using a standardized 
questionnaire based on a CAPI system (Computer- Assisted 
Personal Interview). Detailed information on socioeco-
nomic characteristics, personal medical history and drugs 
use, family history of cancer, diet, tobacco, and alcohol 
consumption, physical activity, and residential and occu-
pational history were gathered.
Cases and controls were asked about their lifetime aspirin 
and NA- NSAIDs consumption, and more specifically about 
the name, the frequency, and the duration of the specific 
NSAID they used. They were also asked about the reason 
of NSAID use and if the use was under medical prescrip-
tion or over the counter.
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For prostate cancer cases, medical information such as 
Gleason score or PSA at diagnosis had been extracted 
from their medical record or from the Hérault Cancer 
Registry.
Statistical analysis
All analyses were performed using SAS 9.4 software (SAS 
Institute Inc., Cary, NC). NSAIDs were divided into three 
categories: overall users (all- NSAIDs), aspirin users (aspi-
rin), and nonaspirin NSAID users (NA- NSAIDs). All- 
NSAIDs users were defined as users of aspirin or 
NA- NSAIDs at least once a month. Men who never took, 
or less than once a month, any kind of NSAIDs were 
considered as nonusers (reference class). The frequency 
of use (<1/day, =1/day, ≥1/day), duration of use (<5 years, 
5–10 years, >10 years), and recency of use (former, cur-
rent) were analyzed for all- NSAIDs, aspirin, and NA- 
NSAIDs users. We also classified NSAIDs according to 
their anti- COX- 1 or anti- COX- 2 preferential activity based 
on the known COX- 1/COX- 2 ratio of each NSAID. Coxib, 
diclofenac, etodolac, and oxicams inhibit preferentially 
COX- 2 (ratio <1), while aspirin, propionates, and indo-
metacin inhibit preferentially COX- 1 [11].
Unconditional logistic regression models were used to 
estimate odds ratios (ORs) and their 95% confidence 
intervals (CIs). Analyses were systematically adjusted for 
age (5- year period), family history of prostate cancer in 
first- degree relatives and race (Caucasians, others). Analyses 
were also adjusted for other potential confounding factors 
such as educational level, body mass index (BMI) (<25/25–
30/≥30) or waist to hip ratio (WHR) (<0.95/≥0.95), and 
personal prostatitis history (no: no personal history of 
prostatitis/yes: at least one personal history of acute or 
chronic prostatitis).
Separate analyses were also conducted by prostate cancer 
aggressiveness according to the Gleason score (low or 
intermediate score ≤7 [including 3 + 4], high score ≥7 
[including 4 + 3]).
Ethics statement
Each subject enrolled in the study provides their written 
informed consent. The EPICAP study was approved by 
the Institutional Review Board of the French National 
Institute of Health and Medical Research (IRB- Inserm 
No. 01- 040, November 2010) and by the French data 
Protection Authority (CNIL No. 910485, April 2011).
Results
The characteristics of prostate cancer cases and controls 
are presented in Table 1. We enrolled 819 prostate cancer 
cases and 879 population- based controls, and among them, 
age distribution in 5- year groups was the same in both 
cases and controls (P = 0.19). Among cases of prostate 
cancer, 76% had a low or intermediate Gleason score ≤7 
(including 3 + 4), and 22% had a high score ≥7 (includ-
ing 4 + 3), that is, aggressive cancer, and among them, 
10% had a Gleason score over 7. Our study population 
was predominantly Caucasian (>95% for both cases and 
controls). Family history of prostate cancer in first- degree 
relatives was more frequent in cases than in controls (22% 
in cases vs. 9% in controls, P < 0.0001), consistent with 
the literature. Considering anthropomorphic data, BMI 
was similar in cases and controls (P = 0.79), while WHR 
was significantly higher in cases than in controls (73% 
of cases vs. 67% of controls, P = 0.03). Personal history 
of certain comorbidities, such as cardiovascular background 
(myocardial infarction, hypertension, stroke, diabetes) and 
rheumatologic background, were similarly distributed 
between cases and controls (P = 0.56, P = 0.52, respec-
tively), while personal history of prostatitis was significantly 
more frequent in cases than in controls (P = 0.02).
Sociodemographic and lifestyle characteristics of all- 
NSAID users and nonusers among controls are shown in 
Table 2. NSAIDs users and nonusers were similar in terms 
of age, family history of prostate cancer in first- degree 
relatives, educational level, and smoking status (P = 0.23, 
P = 0.15, P = 0.31, P = 0.35, respectively). In the con-
trary, NSAIDs users were more likely to have a BMI of 
30 and above, a personal history of prostatitis, a cardio-
vascular or a rheumatologic background than nonusers 
(P = 0.002, P = 0.002, P < 0.0001, P < 0.0001, 
respectively).
We observed that 220 (27%) cases and 272 (31%) 
controls had ever used all- NSAIDs (OR 0.77, 95% CI 
0.61–0.98) (Table 3). The association decreased with the 
frequency of use (OR 0.93, 95% CI 0.68–1.27 for less 
than 1 use per day; OR 0.75, 95% CI 0.54–1.04 for 1 
use per day; OR 0.38, 95% CI 0.18–0.79 for more than 
1 use per day; P trend = 0.003) and was more pronounced 
for a duration of 5–10 years (OR 0.55, 95% CI 0.33–0.92), 
for a current use (OR 0.68, 95% CI 0.50–0.94), and when 
the NSAIDs use had a preferentially anti- COX- 2 activity 
(OR 0.48, 95% CI 0.28–0.79).
Associations for aspirin use and NA- NSAIDs use are 
presented in Table 4. Aspirin use was slightly negatively, 
but not significantly, associated with prostate cancer (OR 
0.86, 95% CI 0.65–1.14). Nevertheless, a frequency of 1 
use per day, a duration of 5–10 years, and a current use 
were significantly negatively associated with prostate cancer 
(OR 0.59, 95% CI 0.39–0.89; OR 0.49, 95% CI 0.27–0.90; 
OR 0.70, 95% CI 0.48–1.00, respectively). NA- NSAIDs 
use was also negatively associated with prostate cancer 
(OR 0.72, 95% CI 0.53–0.99), especially under medical 
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prescription (OR 0.71, 95% CI 0.51–0.97). There was 
neither frequency nor duration clear effect, but current 
use was strongly negatively associated (OR 0.52, 95% CI 
0.30–0.91).
We performed all analyses according to the aggressive-
ness of prostate cancer (Table 5). NA- NSAIDs use was 
negatively associated with aggressive prostate cancer (OR 
0.49, 95% CI 0.27–0.89 vs. OR 0.78, 95% CI 0.56–1.09 
for low or intermediate score); especially NA- NSAID with 
preferential anti- COX- 2 activity (OR 0.33, 95% CI 0.11–
0.94). This association was not found with aspirin use.
Finally, stratifying on history of prostatitis (Table 6), 
the inverse association observed with NSAIDs was rein-
forced among patients with a personal history of prostatitis 
(OR 0.32, 95% CI 0.15–0.71) compared to men with no 
history of prostatitis (OR 0.85, 95% CI 0.67–1.09); espe-
cially among NA- NSAID users (OR 0.21, 95% CI 0.07–0.59 
vs. OR 0.82, 95% CI 0.59–1.12, respectively). Interaction 
was statistically significant for all- NSAIDs use (P = 0.02).
All analyses were also adjusted for the reason of NSAIDs 
use such as cardiovascular and rheumatologic backgrounds, 
and results remained unchanged.
Table 1. Study population characteristics.
Cases 
n = 819 (%)
Controls 
n = 879 (%)
P- value1
Gleason score
≤7 (3 + 4) 623 (76) –
≥7 (4 + 3) 180 (22) –
Age at diagnosis/interview, years 0.19
40–55 48 (6) 59 (7)
55–60 99 (12) 99 (11)
60–65 217 (27) 201 (23)
65–70 274 (33) 285 (32)
70–75 181 (22) 235 (27)
Race 0.43
Caucasian 795 (97) 859 (98)
Other 24 (3) 20 (2)
Family history of prostate cancer at first degree <0.0001
No 549 (67) 723 (82)
Yes 181 (22) 77 (9)
Educational level 0.22
No diploma 70 (9) 72 (8)
Up to high school 376 (46) 436 (50)
High school 113 (14) 110 (13)
College 260 (32) 260 (30)
Smoking status 0.077
Never 240 (29) 246 (28)
Ex- smoker 455 (56) 476 (54)
Smoker 123 (15) 157 (18)
Body mass index (BMI) 0.79
<25 231 (28) 248 (28)
25–29 399 (49) 397 (45)
≥30 182 (22) 207 (24)
Waist to hip ratio (WHR) 0.03
<0.95 214 (26) 265 (30)
≥0.95 594 (73) 590 (67)
Prostatitis history 0.02
No 735 (90) 816 (93)
Yes 84 (10) 63 (7)
Cardiovascular background2 0.56
No 432 (53) 443 (51)
Yes 384 (47) 427 (49)
Rheumatologic background3 0.52
No 626 (78) 662 (77)
Yes 175 (21) 202 (23)
1Adjusted for age.
2Myocardial infarction, hypertension, stroke, diabetes.
3Rheumatoid polyarthritis, spondylarthropathies, arthrosis.
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Discussion
This study showed that NSAIDs consumption was nega-
tively associated with prostate cancer occurrence, with a 
23% reduction in prostate cancer risk, with convincing 
inverse associations of both aspirin and NA- NSAIDs use. 
This association was more pronounced with a frequency 
of one or more pill a day and a current and chronic 
duration for all- NSAIDs users, reaching a 52% decreased 
risk for anti- COX- 2 activity users.
Our results are based on a large carefully designed 
population- based case–control study conducted specifically 
to assess environmental and genetic factors in prostate 
cancer risk. Cases were identified in all cancer hospitals, 
either public or private, that recruited prostate cancer 
patients in the département of Hérault. In 2012, the Hérault 
Cancer Registry observed 770 new cases of prostate cancer, 
of which 575 were under 75 years of age. Considering 
that the number of cases observed in 2011 was identical, 
approximately 1150 new cases were expected during the 




n = 593 (67%)
NSAID users 
n = 272 (31%)
P- value1
Age at diagnosis/interview, years 0.10
40–55 42 (7) 13 (5)
55–60 69 (12) 30 (11)
60–65 141 (24) 58 (21)
65–70 189 (32) 92 (34)
70–75 152 (26) 79 (29)
Race 0.06
Caucasian 583 (98) 262 (96)
Other 10 (2) 10 (4)
Family history of prostate cancer at first degree 0.05
No 495 (83) 215 (79)
Yes 45 (8) 32 (12)
Educational level 0.28
No diploma 45 (8) 24 (9)
Up to high school 295 (50) 134 (49)
High school 69 (11) 39 (14)
College 184 (31) 74 (27)
Smoking status 0.58
Never 169 (29) 76 (28)
Ex- smoker 320 (54) 147 (54)
Smoker 104 (18) 49 (18)
Body mass index (BMI) 0.002
<25 177 (30) 67 (25)
25–29 281 (47) 106 (39)
≥30 122 (21) 85 (31)
Waist to hip ratio (WHR) 0.67
≤95 184 (30) 78 (29)
>95 396 (67) 183 (67)
Prostatitis history 0.002
No 561 (95) 241 (89)
Yes 32 (5) 31 (11)
Cardiovascular background2 <0.0001
No 333 (57) 103 (38)
Yes 255 (43) 165 (61)
Rheumatologic background3 <0.0001
No 476 (81) 175 (64)
Yes 111 (19) 88 (32)
1Adjusted for age.
2Myocardial infarction, hypertension, stroke, diabetes.
3Rheumatoid polyarthritis, spondylarthropathies, arthrosis.
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study period (2012–2013) [31]. We identified 1098 eligible 
cases over the study period suggesting that the recruit-
ment of cases in the EPICAP study was exhaustive, thus 
limiting a potential selection bias. Even though participa-
tion rate in cases was 75%, the age distribution and the 
Gleason score were comparable to those of the Hérault 
Cancer Registry for the years 2009–2011 (private com-
munication), which indicates that cases included in the 
study were representative of all eligible cases. Controls 
were randomly selected from the general population of 
the département of Hérault using quotas on age (5 years) 
to reflect the age distribution of the cases. Moreover, 
quotas by socioeconomic status (SES) have been established 
to yield the control group similar to the general popula-
tion of the département of Hérault of the same age in 
terms of SES. After the selection process, we compared 
the distribution by SES between our control group and 
the male general population of the département of Hérault 
and found no significant difference, indicating that no 
major selection bias by SES had occurred.
To minimize misclassification of exposure, data were 
collected by a trained research clinical nurse using a 
standardized questionnaire. Many details on former and 
current use of NSAIDs with exhaustive questions on name 
of the drug, indication, prescription by a doctor or over 
the counter, frequency, recency, and duration of use were 
collected. In our study, prevalence of exposure to all- 
NSAIDs was 31% among controls which was similar to 
other studies using questionnaires [19,27]. Recall bias is 
often an issue in case–control studies. Nevertheless, the 
use of a standardized questionnaire, a face to face inter-
view by a research clinical nurses, and the fact that cases 
and controls were interviewed under the same conditions 
minimize the possibility of such bias. Moreover, a recall 
bias is usually more frequent in cases than in controls 
which may explain a positive association but not an inverse 
association as we observed in our results.
Our results were unchanged after adjustment for poten-
tial major confounding factors such as family history of 
prostate cancer, anthropometric indicators, or reason for 
NSAIDs use (cardiovascular and rheumatologic back-
grounds), limiting potential confounding.
Detection bias, meaning that patient under NSAIDs 
would have had more frequent contact with doctors and 
therefore more cancers detected could not be excluded, 
but it could have only weakened the association as it 
would have gone toward positive association. In the same 
way, reverse causation bias would have been very unlikely 
to occur as it would have also gone toward a positive 
association.
Finally, an indication bias may have occurred if the 
reason for NSAIDs use (cardiovascular and rheumatologic 
Table 3. Associations between NSAIDs use and prostate cancer risk.
Cases 
n = 819 (%)
Controls 
n = 879 (%)
OR (95% CI)1
All- NSAIDs
Nonuse 596 (73) 593 (67) 1.00
Ever- use 220 (27) 272 (31) 0.77 (0.61–0.98)
Drug issuance
Over the counter 34 (4) 33 (4) 1.00 (0.57–1.75)
Medical prescription 181 (22) 229 (26) 0.76 (0.59–0.98)
Anti- COX activity
Preferential anti- COX- 1 160 (20) 186 (22) 0.85 (0.65–1.11)
Preferential anti- COX- 2 32 (4) 57 (7) 0.48 (0.28–0.79)
Frequency
<1/day 109 (13) 108 (12) 0.93 (0.68–1.27)
=1/day 93 (11) 121 (14) 0.75 (0.54–1.04)
>1/day 11 (1) 30 (3) 0.38 (0.18–0.79)
Duration (years)
<5 62 (8) 81 (9) 0.67 (0.45–0.99)
5–10 33 (4) 53 (6) 0.55 (0.33–0.92)
>10 120 (15) 133 (15) 0.94 (0.69–1.27)
Recency
Former use 119 (15) 125 (14) 0.87 (0.64–1.18)
Current use 101 (12) 147 (17) 0.68 (0.50–0.94)
Current use ≤10 years 41 (5) 69 (8) 0.55 (0.35–0.87)
Current use >10 years 58 (7) 78 (9) 0.79 (0.52–1.20)
Former use ≤10 years 54 (7) 65 (7) 0.69 (0.45–1.06)
Former use >10 years 62 (8) 55 (6) 1.11 (0.73–1.69)
1Adjusted for age, family history of cancer at first degree, race, educational level, history of prostatitis, WHR.
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backgrounds) was associated to prostate cancer. To our 
knowledge, there is no evidence of such an association 
in the literature.
Many observational studies investigated the potential 
protective effect of NSAIDs in cancer and there is striking 
evidence in colorectal cancer through the diminution of 
adenomas incidence (preneoplastic state) in group of 
patients taking NSAIDs, especially anti- COX- 2 or aspirin 
[32–34]. In prostate cancer, results were less convincing 
especially among nonaspirin NSAIDs users. Considering 
aspirin use, our results were consistent with those of recent 
meta- analyses that reported a modest 5–15% reduction 
in prostate cancer risk associated with aspirin use [12, 
14–17]. A recent cohort study observed that low dose of 
aspirin was associated with a decreased risk of prostate 
cancer (HR 0.64, 95% CI 0.48–0.86) especially after at 
least 5 years of use (HR 0.42, 95% CI 0.21–0.91) [35]. 
The Cancer Prevention Study II Nutrition Cohort also 
showed that daily aspirin use for at least 5 years was 
associated to a 15% risk reduction of prostate cancer 
[36].
Regarding NA- NSAIDs, results are less convincing in 
the literature. Our results are consistent with three studies 
reaching statistical significance with inverse association 
(OR 0.71, 95% CI 0.58–0.86) [21, 23, 24] with neither 
duration nor frequency- related trends. A study using the 
Danish registry nationwide data found a slightly increased 
prostate cancer risk among NA- NSAIDs users (OR 1.13, 
95% CI 1.10–1.15) [35], concurring with two Finnish 
studies, one nationwide [37] and one conducted within 
the Finnish Prostate Cancer Screening Trial [20], that 
found an increased risk of prostate cancer associated with 
NA- NSAIDs use, but no apparent trends with either 
increasing cumulative dose or duration of NA- NSAIDs 
use, not supporting causal relationship between NA- 
NSAIDs use and prostate cancer risk. All these positive 
associations could have been due to reverse causation bias 
and detection bias, exposing to the risk of false- positive 
associations. Also, administrative data often lack informa-
tion about confounding factors and sometimes no latency 
is taken into account. Due to important heterogeneity in 
studies, meta- analysis had failed to show inverse associa-
tions of NA- NSAIDs use on prostate cancer [14–16, 29].
Considering grade of cancer, we reported a decreased 
risk of aggressive prostate cancer occurrence in patients 
using all type of NSAIDs (high Gleason score, OR 0.62, 
95% CI 0.41–0.95 vs. intermediate or low Gleason score, 
OR 0.82, 95% CI 0.64–1.06). This is in agreement with 
one study finding significant inverse association of daily 
aspirin taken in the 12 previous months with highly 
aggressive tumors with Gleason score ≥7 or Stage III or 
IV (OR 0.88, 95% CI 0.78–0.99 vs. less aggressive tumors 
OR 0.94, 95% CI 0.85–1.04) and another showing sig-
nificant inverse association with all type of NSAID use 
and tumors with Gleason score ≥7 (OR 0.80, 95% CI 
0.64–0.99) versus no association for Gleason score <7 
Table 4. Associations between aspirin, NA-NSAIDs use, and prostate cancer risk.
Aspirin NA- NSAIDs
Cases 
n = 819 (%)
Controls 
n = 879 (%)
OR (95% CI)1 Cases 
n = 819 (%)
Controls 
n = 879 (%)
OR (95% CI)1
Nonuse 596 (73) 593 (67) 1.00 596 (73) 593 (67) 1.00
Ever- use 143 (17) 166 (19) 0.86 (0.65–1.14) 107 (13) 143 (16) 0.72 (0.53–0.99)
Drug issuance
Over the counter 39 (5) 41 (5) 0.91 (0.54–1.53) 2 (0) 2 (0) 1.96 (0.17–22.7)
Medical prescription 102 (12) 120 (14) 0.86 (0.62–1.19) 100 (12) 136 (15) 0.71 (0.51–0.97)
Frequency
<1 /day 83 (10) 58 (7) 1.39 (0.93–2.06) 49 (6) 72 (8) 0.70 (0.46–1.06)
=1/day 54 (7) 90 (10) 0.59 (0.39–0.89) 43 (5) 40 (5) 0.88 (0.53–1.45)
>1/day 4 (0) 13 (1) 0.32 (0.10–1.03) 8 (1) 18 (2) 0.53 (0.22–1.30)
Duration (years)
<5 33 (4) 43 (5) 0.66 (0.38–1.13) 38 (5) 56 (6) 0.70 (0.43–1.13)
5–10 23 (3) 41 (5) 0.49 (0.27–0.90) 16 (2) 19 (2) 0.88 (0.40–1.93)
>10 85 (10) 81 (9) 1.14 (0.79–1.65) 49 (6) 64 (7) 0.70 (0.45–1.09)
Recency
Former use 66 (8) 59 (7) 1.11 (0.73–1.67) 81 (10) 94 (11) 0.82 (0.58–1.18)
Current use 77 (9) 107 (12) 0.70 (0.48–1.00) 26 (3) 49 (6) 0.52 (0.30–0.91)
Current use ≤10 years 32 (4) 55 (6) 0.54 (0.32–0.90) 10 (1) 21 (2) 0.41 (0.17–1.00)
Current use >10 years 43 (5) 52 (6) 0.85 (0.52–1.40) 16 (2) 28 (3) 0.61 (0.30–1.23)
Former use ≤10 years 24 (3) 29 (3) 0.64 (0.34–1.22) 44 (5) 54 (6) 0.88 (0.55–1.41)
Former use >10 years 42 (5) 29 (3) 1.60 (0.94–2.71) 33 (4) 36 (4) 0.76 (0.44–1.31)
1Adjusted for age, family history of cancer at first degree, race, educational level, history of prostatitis, WHR.
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(OR 0.90, 95% CI 0.77–1.04). The Danish study showed 
no real trend considering Gleason score [35]. Regarding 
anti- COX- 2 activity, no special effect was found in the 
literature [38], except one case–control study focusing on 
coxibs that found a 55% significant decreased risk of 
prostate cancer, which is consistent with our findings [39].
Interestingly, the inverse association observed with all- 
NSAIDs use was more pronounced in men with a personal 
history of prostatitis reinforcing the hypothesis that inflam-
mation provides favorable conditions for carcinogenesis 
[40, 41].
In conclusion, our study provides convincing evidence 
that a frequent and chronic NSAIDs use decreased the 
risk of prostate cancer, especially aggressive prostate cancer. 
The specific decreased risk observed among men with a 
personal history is an additional evidence that targeting 
chronic inflammation may help preventing prostate 
carcinogenesis.
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